Rituxan (rituximab) is a cancer medicine that interferes with the growth and spread of cancer cells in the body. It is also used to treat other non-cancer conditions.
Rituxan is an intravenous (IV) infusion given by a healthcare professional. It is a prescription medicine used alone or in combination with other medicines to treat the following conditions:
non-Hodgkin's lymphoma or chronic lymphocytic leukemia in adults;
rheumatoid arthritis in adults;
granulomatosis with polyangiitis and microscopic polyangiitis (rare disorders that cause inflammation of blood vessels and other tissues in the body) in adults and children 2 years of age and older; or
pemphigus vulgaris (a severe autoimmune reaction that causes blisters and breakdown of the skin and mucous membranes) in adults
First Infusion: Initiate infusion at a rate of 50 mg/hr. In the absence of infusion toxicity, increase infusion rate by 50 mg/hr increments every 30 minutes, to a maximum of 400 mg/hr.
Standard Infusion: Initiate infusion at a rate of 100 mg/hr. In the absence of infusion toxicity, increase rate by 100 mg/hr increments at 30-minute intervals, to a maximum of 400 mg/hr.
For Previously Untreated Follicular NHL and DLBCL patients: If patients did not experience a Grade 3 or 4 infusion-related adverse event during Cycle 1, a 90-minute infusion can be administered in Cycle 2 with a glucocorticoid-containing chemotherapy regimen.
Initiate at a rate of 20% of the total dose given in the first 30 minutes and the remaining 80% of the total dose given over the next 60 minutes. If the 90-minute infusion is tolerated in Cycle 2, the same rate can be used when administering the remainder of the treatment regimen (through Cycle 6 or 8).
Patients who have clinically significant cardiovascular disease or who have a circulating lymphocyte count ≥5000/mm3 before Cycle 2 should not be administered the 90-minute infusion